HDM1002 vs orforglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
HDM1002
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
orforglipron · Foundayo
Marketed by Eli Lilly and partners
NCT05803421 · Phase 3 · completed
ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.
Next expected readout: February 2027 · NCT06672549 (registry estimate)
Reported efficacy
Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)
Result source: NCT05872620
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HDM1002 | orforglipron |
|---|---|---|
| Body weight, % change | —Trial running · NCT06885021 | -7.9% vs -0.6%−7.3 vs placeboNCT0593138011 other results
|
| Weight loss of 5% or more | —Trial running · NCT06885021 | 58.3% vs 15%+43.3 vs placeboNCT0593138010 other results
|
| Weight loss of 10% or more | —Trial running · NCT06885021 | 38.3% vs 3.3%+35 vs placeboNCT0593138010 other results
|
| Waist circumference, change (cm) | —Trial running · NCT06885021 | -5.7 vs -0.1−5.6 vs placeboNCT0593138012 other results
|
Body weight, % change
- HDM1002
- —Trial running · NCT06885021
- orforglipron
- -7.9% vs -0.6%−7.3 vs placeboNCT05931380
11 other results
- -8.7% vs -0.6% NCT05931380
- -5.9% vs -0.6% NCT05931380
- -12.3% vs -2% NCT05051579
- -8.6% vs -2% NCT05051579
- -12.6% vs -2% NCT05051579
- -11.2% vs -2% NCT05051579
- -13.5% vs -2.3% NCT05051579
- -9.4% vs -2.3% NCT05051579
- -14.7% vs -2.3% NCT05051579
- -12.5% vs -2.3% NCT05051579
- -9.6% vs -2.5% NCT05872620
Weight loss of 5% or more
- HDM1002
- —Trial running · NCT06885021
- orforglipron
- 58.3% vs 15%+43.3 vs placeboNCT05931380
10 other results
- 61.4% vs 15% NCT05931380
- 45.9% vs 15% NCT05931380
- 92.0% vs 24.0% NCT05051579
- 89.5% vs 22.9% NCT05051579
- 72% vs 24.0% NCT05051579
- 74.4% vs 22.9% NCT05051579
- 90.4% vs 24.0% NCT05051579
- 87.3% vs 22.9% NCT05051579
- 89.5% vs 24.0% NCT05051579
- 88.8% vs 22.9% NCT05051579
Weight loss of 10% or more
- HDM1002
- —Trial running · NCT06885021
- orforglipron
- 38.3% vs 3.3%+35 vs placeboNCT05931380
10 other results
- 35.1% vs 3.3% NCT05931380
- 18.0% vs 3.3% NCT05931380
- 74.8% vs 8.8% NCT05051579
- 71.3% vs 2.3% NCT05051579
- 46.5% vs 8.8% NCT05051579
- 39.4% vs 2.3% NCT05051579
- 69.1% vs 8.8% NCT05051579
- 69.9% vs 2.3% NCT05051579
- 61.9% vs 8.8% NCT05051579
- 56.6% vs 2.3% NCT05051579
Waist circumference, change (cm)
- HDM1002
- —Trial running · NCT06885021
- orforglipron
- -5.7 vs -0.1−5.6 vs placeboNCT05931380
12 other results
- -5.9 vs -0.1 NCT05931380
- -3.7 vs -0.1 NCT05931380
- -10.6 vs -4 NCT05051579
- -10.1 vs -3.6 NCT05051579
- -9.6 vs -4 NCT05051579
- -8 vs -3.6 NCT05051579
- -13.6 vs -4 NCT05051579
- -12.2 vs -3.6 NCT05051579
- -11.2 vs -4 NCT05051579
- -8.8 vs -3.6 NCT05051579
- -5.8 NCT06023095
- -11.7 NCT06023095
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HDM1002: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HDM1002: 0 of 4 rows · orforglipron: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | orforglipron |
|---|---|
| Dropout rate | 10%36 mg QDa NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results8.8%12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 11.5%6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 12%12 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 13.2%24 mg NCT05051579 · Phase 2 · registry result, not featured evidence —17.2 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —14.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —9 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —5.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —2.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —0.8 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 1) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 2) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 3) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 4) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 5) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 6) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 7) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 8) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 9) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 10) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 12) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 13) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 14) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 15) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 16) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 18) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 11) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 17) NCT06440980 · Phase 1 · registry result, not featured evidence 10%LY3502970 (Cohort 1) NCT06023095 · Phase 1 · registry result, not featured evidence 10%LY3502970 (Cohort 2) NCT06023095 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg + 0.2 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg DF capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg EPB capsule NCT05841238 · Phase 1 · registry result, not featured evidence —60 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —45 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —20 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —16 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —10 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —8 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —0.8 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 1 NCT05313802 · Phase 1 · registry result, not featured evidence 4.2%LY3502970 Cohort 2 NCT05313802 · Phase 1 · registry result, not featured evidence 8.3%LY3502970 Cohort 3 NCT05313802 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 3.3%36 mg QDa NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results3.5%12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 1.6%6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 4%12 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 1.9%24 mg NCT05051579 · Phase 2 · registry result, not featured evidence —17.2 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —14.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —9 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —5.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —2.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —0.8 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 1) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 2) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 3) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 4) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 5) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 6) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 7) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 8) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 9) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 10) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 12) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 13) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 14) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 15) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 16) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 18) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 11) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 17) NCT06440980 · Phase 1 · registry result, not featured evidence 0%LY3502970 (Cohort 1) NCT06023095 · Phase 1 · registry result, not featured evidence 10%LY3502970 (Cohort 2) NCT06023095 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg + 0.2 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg DF capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg EPB capsule NCT05841238 · Phase 1 · registry result, not featured evidence —60 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —45 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —20 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —16 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —10 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —8 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —0.8 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 1 NCT05313802 · Phase 1 · registry result, not featured evidence 4.2%LY3502970 Cohort 2 NCT05313802 · Phase 1 · registry result, not featured evidence 4.2%LY3502970 Cohort 3 NCT05313802 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 10%36 mg QDa NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results5.3%12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 1.6%6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 0%36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 10.3%36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 0%12 mg NCT05051579 · Phase 2 · registry result, not featured evidence 6.5%45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 3.8%24 mg NCT05051579 · Phase 2 · registry result, not featured evidence 0%17.2 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0.6%36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0.5%6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%14.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%9 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0.5%5.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%2.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%0.8 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 1) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 2) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 3) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 4) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 5) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 6) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 7) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 8) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 9) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 10) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 12) NCT06440980 · Phase 1 · registry result, not featured evidence 2%tablet QD (dose level 13) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 14) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 15) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 16) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 18) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 11) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 17) NCT06440980 · Phase 1 · registry result, not featured evidence 0%LY3502970 (Cohort 1) NCT06023095 · Phase 1 · registry result, not featured evidence 0%LY3502970 (Cohort 2) NCT06023095 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 5.3%12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg + 0.2 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%1 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 2.2%36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%36 mg DF capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%36 mg EPB capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%60 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%45 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 2.2%20 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%16 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%10 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%8 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%2.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%2 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%0.8 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 1 NCT05313802 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 2 NCT05313802 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 3 NCT05313802 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 36 mg QDa nausea 33.3% (placebo 0%) constipation 31.7% (placebo 8.3%) nasopharyngitis 20% (placebo 35%) NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results12 mg QD nasopharyngitis 42.1% (placebo 35%) constipation 28.1% (placebo 8.3%) nausea 15.8% (placebo 0%) NCT05931380 · Phase 3 · registry result, not featured evidence 6 mg QD constipation 36.1% (placebo 8.3%) nasopharyngitis 26.2% (placebo 35%) diarrhoea 14.8% (placebo 3.3%) NCT05931380 · Phase 3 · registry result, not featured evidence 36 mg nausea 41.4% (placebo 10%) constipation 27.6% (placebo 6%) vomiting 27.6% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 36 mg nausea 48.3% (placebo 10%) constipation 24.1% (placebo 6%) covid-19 24.1% (placebo 18%) NCT05051579 · Phase 2 · registry result, not featured evidence 12 mg nausea 50% (placebo 10%) vomiting 26% (placebo 6%) constipation 24% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 45 mg nausea 41.9% (placebo 10%) vomiting 29% (placebo 6%) constipation 19.4% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 45 mg nausea 36.7% (placebo 10%) diarrhoea 33.3% (placebo 10%) vomiting 26.7% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 24 mg nausea 58.5% (placebo 10%) diarrhoea 35.8% (placebo 10%) constipation 32.1% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 17.2 mg tablet QD vomiting 5.7% headache 3.4% nausea 3.4% NCT06440980 · Phase 1 · registry result, not featured evidence 36 mg capsule QD headache 6.7% constipation 4.4% dizziness 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence 36 mg capsule QD headache 15.9% vomiting 10.8% diarrhoea 6.3% NCT06440980 · Phase 1 · registry result, not featured evidence 12 mg capsule QD constipation 6% nausea 6% headache 4% NCT06440980 · Phase 1 · registry result, not featured evidence 12 mg capsule QD constipation 21% headache 19.4% nausea 17.2% NCT06440980 · Phase 1 · registry result, not featured evidence 6 mg capsule QD headache 8.7% dyspepsia 4.3% vomiting 4.3% NCT06440980 · Phase 1 · registry result, not featured evidence 6 mg capsule QD headache 12.3% nausea 9.4% dyspepsia 7.9% NCT06440980 · Phase 1 · registry result, not featured evidence 24 mg capsule QD headache 10% vomiting 6% abdominal pain 4% NCT06440980 · Phase 1 · registry result, not featured evidence 24 mg capsule QD nausea 17.1% diarrhoea 12.7% constipation 10.5% NCT06440980 · Phase 1 · registry result, not featured evidence 14.5 mg tablet QD headache 8.3% nausea 8.3% diarrhoea 6.7% NCT06440980 · Phase 1 · registry result, not featured evidence 9 mg tablet QD headache 9.7% constipation 9.1% vomiting 8.1% NCT06440980 · Phase 1 · registry result, not featured evidence 5.5 mg tablet QD headache 8.4% nausea 8.4% constipation 4.9% NCT06440980 · Phase 1 · registry result, not featured evidence 3 mg capsule QD nausea 4.3% decreased appetite 2.1% diarrhoea 2.1% NCT06440980 · Phase 1 · registry result, not featured evidence 3 mg capsule QD headache 17.6% nausea 13.8% constipation 9.5% NCT06440980 · Phase 1 · registry result, not featured evidence 2.5 mg tablet QD headache 8.1% constipation 6.2% nausea 6.2% NCT06440980 · Phase 1 · registry result, not featured evidence 1 mg capsule QD constipation 7.7% decreased appetite 1.9% eructation 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence 1 mg capsule QD constipation 27% headache 15.8% nausea 6% NCT06440980 · Phase 1 · registry result, not featured evidence 0.8 mg tablet QD constipation 8.9% headache 8.9% dyspepsia 4.7% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 1) constipation 9.6% diarrhoea 1.9% eructation 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 2) abdominal pain 3.8% diarrhoea 3.8% constipation 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 3) constipation 13.5% abdominal distension 1.9% dizziness 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 4) nausea 7.8% vomiting 7.8% constipation 5.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 5) nausea 8.3% dyspepsia 6.3% headache 6.3% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 6) diarrhoea 5.9% abdominal pain 3.9% constipation 3.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 7) nausea 6.5% dyspepsia 4.3% headache 4.3% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 8) dyspepsia 6.4% headache 4.3% nausea 4.3% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 9) nausea 10.9% abdominal distension 6.5% abdominal pain 6.5% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 10) constipation 8% diarrhoea 6% dyspepsia 6% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 12) nausea 8% headache 6% diarrhoea 4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 13) constipation 8.2% abdominal pain 4.1% diarrhoea 4.1% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 14) dizziness 12.2% headache 6.1% abdominal pain 4.1% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 15) nausea 8% constipation 4% diarrhoea 4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 16) heart rate increased 8.9% constipation 4.4% headache 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 18) constipation 6.7% diarrhoea 6.7% nausea 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 11) dyspepsia 6% constipation 4% diarrhoea 4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 17) nausea 13.3% headache 6.7% diarrhoea 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence decreased appetite 70% (placebo 50%) diarrhoea 60% (placebo 25%) eructation 40% (placebo 0%) NCT06023095 · Phase 1 · registry result, not featured evidence nausea 80% (placebo 0%) decreased appetite 70% (placebo 50%) diarrhoea 70% (placebo 25%) NCT06023095 · Phase 1 · registry result, not featured evidence 36 mg constipation 4.5% diarrhoea 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg abdominal pain upper 4.5% dizziness 4.5% vomiting 4.5% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD back pain 4.5% diarrhoea 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD constipation 23.1% nausea 11.5% abdominal pain 7.7% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD constipation 22.2% alopecia 5.6% diarrhoea 5.6% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD anxiety 6.3% constipation 6.3% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence 12 mg QD alanine aminotransferase increased 3.8% aspartate aminotransferase increased 3.8% fatigue 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 12 mg QD back pain 5.3% constipation 5.3% cough 5.3% NCT06186622 · Phase 1 · registry result, not featured evidence 6 mg QD dyspepsia 7.7% nausea 7.7% diarrhoea 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 6 mg QD fatigue 15.8% eructation 10.5% headache 10.5% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg + 0.2 mg dizziness 4.8% headache 4.8% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 0.25 mg nausea 9.1% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg decreased appetite 4.5% headache 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 1000 mg headache 4.5% nausea 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 0.25 mg constipation 6.3% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg abdominal pain upper 6.3% abdominal pain 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg dysmenorrhoea 6.3% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 24 mg QD abdominal pain 3.8% diarrhoea 3.8% headache 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 24 mg QD constipation 5.6% diarrhoea 5.6% eructation 5.6% NCT06186622 · Phase 1 · registry result, not featured evidence 20 mg + 20 mg alanine aminotransferase increased 9.1% aspartate aminotransferase increased 9.1% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 20 mg + 20 mg alanine aminotransferase increased 12.5% aspartate aminotransferase increased 12.5% headache 6.3% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 3 mg QD diarrhoea 3.8% fatigue 3.8% nausea 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 3 mg QD abdominal pain 10% nausea 10% alanine aminotransferase increased 5% NCT06186622 · Phase 1 · registry result, not featured evidence 1 mg QD medication error 7.4% dysmenorrhoea 3.7% fatigue 3.7% NCT06186622 · Phase 1 · registry result, not featured evidence 1 mg + 1000 mg headache 3.7% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 1 mg QD eructation 15% decreased appetite 10% headache 10% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg capsule nausea 9.5% abdominal pain 4.8% constipation 4.8% NCT05841238 · Phase 1 · registry result, not featured evidence 36 mg capsule diarrhoea 4.4% abdominal pain 2.2% abdominal distension 0% NCT05841238 · Phase 1 · registry result, not featured evidence 36 mg DF capsule constipation 8.3% diarrhoea 8.3% nausea 8.3% NCT05841238 · Phase 1 · registry result, not featured evidence 36 mg EPB capsule nausea 41.7% headache 16.7% diarrhoea 8.3% NCT05841238 · Phase 1 · registry result, not featured evidence 60 mg tablet vomiting 14.3% constipation 4.8% dyspepsia 4.8% NCT05841238 · Phase 1 · registry result, not featured evidence 45 mg tablet abdominal distension 9.5% nausea 9.5% vomiting 4.8% NCT05841238 · Phase 1 · registry result, not featured evidence 37.5 mg tablet headache 19% nausea 19% constipation 9.5% NCT05841238 · Phase 1 · registry result, not featured evidence 37.5 mg tablet nausea 14.6% headache 12.2% vomiting 12.2% NCT05841238 · Phase 1 · registry result, not featured evidence 35 mg tablet dyspepsia 14.3% flatulence 14.3% nausea 14.3% NCT05841238 · Phase 1 · registry result, not featured evidence 35 mg tablet intertrigo 14.3% abdominal distension 0% abdominal pain 0% NCT05841238 · Phase 1 · registry result, not featured evidence 20 mg tablet dyspepsia 4.3% abdominal pain 2.2% diarrhoea 2.2% NCT05841238 · Phase 1 · registry result, not featured evidence 16 mg capsule diarrhoea 6.5% vomiting 2.2% abdominal distension 0% NCT05841238 · Phase 1 · registry result, not featured evidence 10 mg tablet constipation 12.2% nausea 4.1% dyspepsia 2% NCT05841238 · Phase 1 · registry result, not featured evidence 8 mg capsule dyspepsia 10.2% decreased appetite 6.1% diarrhoea 6.1% NCT05841238 · Phase 1 · registry result, not featured evidence 5 mg tablet headache 12% dyspepsia 4% abdominal pain 2% NCT05841238 · Phase 1 · registry result, not featured evidence 2.5 mg tablet headache 4% decreased appetite 2% gastrooesophageal reflux disease 2% NCT05841238 · Phase 1 · registry result, not featured evidence 2 mg capsule constipation 10% diarrhoea 2% abdominal distension 0% NCT05841238 · Phase 1 · registry result, not featured evidence 0.8 mg tablet constipation 3.8% headache 3.8% nausea 3.8% NCT05841238 · Phase 1 · registry result, not featured evidence constipation 37.5% headache 33.3% weight decreased 25% NCT05313802 · Phase 1 · registry result, not featured evidence dyspepsia 41.7% constipation 33.3% weight decreased 29.2% NCT05313802 · Phase 1 · registry result, not featured evidence constipation 25% dyspepsia 25% headache 16.7% NCT05313802 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
orforglipron
show 11 more results
show 10 more results
show 10 more results
show 2 more results
show 2 more results
show 12 more results
show 2 more results
show 2 more results
show 12 more results
show 2 more results
show 2 more results
show 2 more results
+ 8 further endpoints in the CSV export.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
HDM1002
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07082114 (registry estimate)
No aligned efficacy figure on record for this race.
orforglipron · Foundayo
Marketed by Eli Lilly and partners
NCT05803421 · Phase 3 · completed
ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.
Next expected readout: May 2027 · NCT07613307 (registry estimate)
Reported efficacy
Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)
Result source: NCT05872620
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HDM1002 | orforglipron |
|---|---|---|
| HbA1c, change | —Trial running · NCT07082114 | -1.4% vs -0.1%−1.3 vs placeboNCT0597194014 other results
|
| Body weight, change (kg) | —Trial running · NCT07082114 | -7.3 vs -1.3−6 vs placeboNCT059719407 other results
|
| HbA1c below 7% | —Trial running · NCT07082114 | 79.0% vs 37.1%+41.9 vs placeboNCT059719407 other results
|
| Fasting plasma glucose, change | —Trial running · NCT07082114 | -2.0 vs -1.1−0.9 vs placeboNCT044264744 other results
|
| 3-point MACE (% with event) | —Trial running · NCT07082114 | —Not posted · NCT05803421 |
HbA1c, change
- HDM1002
- —Trial running · NCT07082114
- orforglipron
- -1.4% vs -0.1%−1.3 vs placeboNCT05971940
14 other results
- -1.6% vs -0.1% NCT05971940
- -1.3% vs -0.1% NCT05971940
- -2.0% vs -0.4% NCT05048719
- -1.9% vs -0.4% NCT05048719
- -1.2% vs -0.4% NCT05048719
- -2.1% vs -0.4% NCT05048719
- -1.8% vs -0.4% NCT05048719
- -2.0% vs -1.1% NCT05048719
- -1.9% vs -1.1% NCT05048719
- -1.2% vs -1.1% NCT05048719
- -2.1% vs -1.1% NCT05048719
- -1.8% vs -1.1% NCT05048719
- -1.7% vs -0.5% NCT05872620
- 1.7% vs 0.8% NCT06192108
Body weight, change (kg)
- HDM1002
- —Trial running · NCT07082114
- orforglipron
- -7.3 vs -1.3−6 vs placeboNCT05971940
7 other results
- -5.5 vs -1.3 NCT05971940
- -4.4 vs -1.3 NCT05971940
- -9.5 vs -2.2 NCT05048719
- -6.5 vs -2.2 NCT05048719
- -3.7 vs -2.2 NCT05048719
- -10.1 vs -2.2 NCT05048719
- -9.7 vs -2.2 NCT05048719
HbA1c below 7%
- HDM1002
- —Trial running · NCT07082114
- orforglipron
- 79.0% vs 37.1%+41.9 vs placeboNCT05971940
7 other results
- 81.3% vs 37.1% NCT05971940
- 78.2% vs 37.1% NCT05971940
- 92.8% vs 24.3% NCT05048719
- 78.9% vs 24.3% NCT05048719
- 65.2% vs 24.3% NCT05048719
- 95.8% vs 24.3% NCT05048719
- 91.2% vs 24.3% NCT05048719
Fasting plasma glucose, change
- HDM1002
- —Trial running · NCT07082114
- orforglipron
- -2.0 vs -1.1−0.9 vs placeboNCT04426474
4 other results
- -3 vs -1.1 NCT04426474
- -2.9 vs -1.1 NCT04426474
- -2.4 vs -1.1 NCT04426474
- -2.3 vs -1.1 NCT04426474
3-point MACE (% with event)
- HDM1002
- —Trial running · NCT07082114
- orforglipron
- —Not posted · NCT05803421
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HDM1002: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HDM1002: 0 of 4 rows · orforglipron: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | orforglipron |
|---|---|
| Dropout rate | 6.7%36 mga NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results5.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 5.3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3.5%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 8.8%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 6.3%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 7.4%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 11.8%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.7%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 7.8%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 6.5%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 9.4%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 57.1%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 2.2%36 mga NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results4.4%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.5%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.4%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0.7%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.6%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 35.7%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 4.5%36 mga NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results2.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 2.8%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.1%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.6%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2.9%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 1.8%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 5.9%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.1%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%3 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 36 mga constipation 29.1% nausea 27.6% nasopharyngitis 16.4% NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results12 mg constipation 30.4% nasopharyngitis 22.2% nausea 19.3% NCT06010004 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 17.4% constipation 16.7% nausea 12.9% NCT06010004 · Phase 3 · registry result, not featured evidence 36 mg diarrhoea 25.5% (placebo 9.4%) diabetic retinopathy 17% (placebo 15.2%) nausea 17% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 12 mg diarrhoea 21.2% (placebo 9.4%) dyspepsia 21.2% (placebo 7.2%) nausea 19% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 3 mg diarrhoea 18.9% (placebo 9.4%) diabetic retinopathy 14.7% (placebo 15.2%) nausea 12.6% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 36 mg nausea 37% (placebo 5.5%) vomiting 33.3% (placebo 1.8%) diarrhoea 25.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 36 mg nausea 26.5% (placebo 5.5%) vomiting 20.6% (placebo 1.8%) eructation 8.8% (placebo 0%) NCT05048719 · Phase 2 · registry result, not featured evidence 12 mg nausea 37.5% (placebo 5.5%) vomiting 21.4% (placebo 1.8%) diarrhoea 16.1% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 23.5% (placebo 5.5%) diarrhoea 21.6% (placebo 7.3%) constipation 13.7% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg vomiting 35.5% (placebo 1.8%) diarrhoea 29% (placebo 7.3%) nausea 29% (placebo 5.5%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg diarrhoea 28.1% (placebo 7.3%) nausea 25% (placebo 5.5%) vomiting 21.9% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 24 mg nausea 34% (placebo 5.5%) vomiting 27.7% (placebo 1.8%) diarrhoea 14.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 55.6% (placebo 25%) constipation 33.3% (placebo 0%) vomiting 22.2% (placebo 25%) NCT05086445 · Phase 1 · registry result, not featured evidence 2 mg vomiting 40% (placebo 25%) nausea 30% (placebo 25%) abdominal distension 20% (placebo 0%) NCT05086445 · Phase 1 · registry result, not featured evidence 3/6/12/15 mg QD nausea 50% (placebo 5.9%) vomiting 50% (placebo 0%) decreased appetite 40% (placebo 11.8%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21 mg QD nausea 42.9% (placebo 5.9%) decreased appetite 28.6% (placebo 11.8%) covid-19 21.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21/27 mg QD decreased appetite 55.6% (placebo 11.8%) vomiting 55.6% (placebo 0%) nausea 33.3% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9 mg QD vomiting 55.6% (placebo 0%) decreased appetite 44.4% (placebo 11.8%) nausea 44.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9/21/36/45 mg QD nausea 77.8% (placebo 5.9%) decreased appetite 66.7% (placebo 11.8%) vomiting 55.6% (placebo 0%) NCT04426474 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
orforglipron
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HDM1002's landscape · orforglipron's landscape